STAT+: Pharmalittle: SEC probes Cassava over Alzheimer’s drug results; Teva takes pharma in a new direction with a bond sale

Rise and shine, everyone. Another busy day is on the way. We can tell because the hum of life is seen and heard outside our window — garbage trucks are rumbling by, dog walkers are promenading up and back, and car horns are blaring on nearby streets. As for us, we are engaged in our usual morning ritual of brewing cups of stimulation. Our choice today is the ever-seasonal pumpkin spice. Feel free to join us. Meanwhile, here are a few tidbits to help you cope on your own journey. We hope you have a smashing day and, as always, do keep in touch. …

The U.S. Securities and Exchange Commission is investigating claims Cassava Sciences (SAVA) manipulated research results of its experimental Alzheimer’s drug, The Wall Street Journal reports. Cassava disclosed in a securities filing it is cooperating with government investigations. The U.S. National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims. The accusations appeared in a petition filed in August to the U.S. Food and Drug Administration asking it to suspend Cassava clinical trials. The petitioners are two doctors who doubt Cassava research and shorted its stock.

Continue to STAT+ to read the full story…